United States Drug Patent 9,737,469: Scope, Claims, Expiration and Patent Landscape for Baricitinib Hair-Loss Uses

U.S. Patent No. 9,737,469 protects methods of using LY3009104, also known as baricitinib, to treat hair-loss disorders or induce hair growth. The patent is directed to therapeutic use, not to the baricitinib molecule, its salts, dosage forms, manufacturing process, or a particular formulation. Its commercially important coverage is alopecia areata, including severe forms such as alopecia totalis and alopecia universalis.

The patent issued September 5, 2017, from U.S. application publication 2015/0125471. Based on the patent’s 2014 nonprovisional filing date, its ordinary expiration is projected to be November 4, 2034, subject to any applicable patent-term adjustment, terminal disclaimer, or other USPTO record entry.[1]

What does U.S. Patent 9,737,469 protect?

The patent covers administering baricitinib to a mammalian subject for hair loss or hair growth. The independent claims are functional method claims with no express limitation to a particular dose, route of administration, formulation, disease severity, or treatment duration.

Patent element	Scope under the issued claims
Active ingredient	LY3009104, baricitinib
Pharmacologic class	JAK1, JAK2, or JAK3 inhibitor
Protected activity	Treatment of a hair-loss disorder or induction of hair growth
Covered subject	Mammalian subject; some dependent claims narrow this to humans
Express disorders	Androgenetic alopecia, telogen effluvium, alopecia areata, tinea capitis, hypotrichosis, and hereditary hypotrichosis simplex
Severe alopecia areata	Alopecia totalis and alopecia universalis
Dosage limitation	None stated in the claims provided
Route limitation	None stated in the claims provided
Formulation limitation	None stated
Combination-treatment limitation	None stated
Geographic scope	United States

The practical scope is narrower than the broad JAK-inhibitor language may suggest. Each independent claim expressly requires that the inhibitor be LY3009104. A competing product containing ritlecitinib, deuruxolitinib, ruxolitinib, tofacitinib, or another JAK inhibitor would not fall within the literal scope merely because it acts on the same pathway.

How do the independent claims work?

Claim 1: treatment of hair-loss disorders

Claim 1 requires:

A mammalian subject in need of treatment;
Administration of an effective amount of a JAK1, JAK2, or JAK3 inhibitor; and
The inhibitor must be LY3009104.

The claim covers treatment of a hair-loss disorder. It does not require that the patient have alopecia areata, that the treatment be approved by FDA, or that a particular clinical endpoint be achieved, although ordinary method-of-treatment principles would still require performance of the claimed therapeutic steps.

Because LY3009104 is expressly identified, claim 1 is a species claim directed to baricitinib within the broader pharmacologic category of JAK inhibitors. The JAK-class language provides technical context but does not expand the claim to every JAK inhibitor.

Claim 7: inducing hair growth

Claim 7 is the second independent claim. It requires administering an effective amount of LY3009104 and thereby inducing hair growth.

This claim is potentially broader in disease framing because it does not, on its face, require that the subject have a diagnosed hair-loss disorder. A treatment intended to induce hair growth could therefore present a claim issue even where the patient is not coded as having alopecia, provided the factual conduct satisfies the other claim elements.

The phrase “thereby inducing hair growth” creates a causal treatment limitation. The claimant would generally need to show that administration was directed to, and capable of producing, the claimed hair-growth result. The claim is not limited to regrowth in a particular scalp region or to a defined percentage increase in hair density.

What do the dependent claims add?

Claims 2 through 6 and 8 through 11 narrow the independent claims by specifying diseases or patient populations.

Claim	Added limitation
2	Lists androgenetic alopecia, telogen effluvium, alopecia areata, tinea capitis, hypotrichosis, and hereditary hypotrichosis simplex
3	Limits alopecia areata to alopecia totalis or alopecia universalis
4	Limits the subject to a human
5	Limits the human subject to androgenetic alopecia
6	Limits treatment to alopecia areata
8	Limits claim 7 to subjects with a listed hair-loss disorder
9	Limits alopecia areata to alopecia totalis or alopecia universalis
10	Limits the disorder to androgenetic alopecia
11	Limits the disorder to alopecia areata

The repeated listing of telogen effluvium in claim 2 appears to be a drafting or transcription duplication. It does not materially expand the claim.

Claims 5, 6, 10, and 11 are commercially important because they isolate androgenetic alopecia and alopecia areata. Claims 3 and 9 are directed to the most severe alopecia areata phenotypes.

What diseases are covered by Patent 9,737,469?

The patent expressly identifies several hair-loss conditions:

Alopecia areata
Alopecia totalis
Alopecia universalis
Androgenetic alopecia
Telogen effluvium
Tinea capitis
Hypotrichosis
Hereditary hypotrichosis simplex

The claims do not distinguish between male and female androgenetic alopecia. They also do not specify disease duration, prior treatment failure, baseline Severity of Alopecia Tool score, or age, except that the subject must be mammalian and, in certain claims, human.

The strongest current commercial overlap is alopecia areata because FDA approved baricitinib under the Olumiant brand for adults with severe alopecia areata in 2022.[2] The FDA-approved indication creates a direct relationship between the patent’s claimed method and the product’s approved labeling.

When does U.S. Patent 9,737,469 expire?

The projected ordinary expiration date is November 4, 2034.

Event	Date
Earliest identified priority date	November 4, 2013
U.S. nonprovisional filing date	November 4, 2014
U.S. publication	2015
Grant	September 5, 2017
Projected ordinary expiration	November 4, 2034

U.S. patent term for applications filed after June 8, 1995, generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and related statutory rules.[3] The provisional priority date does not itself establish a 20-year expiration date.

The patent is separate from baricitinib composition-of-matter and basic-use patents. Accordingly, the expiration of a composition patent would not necessarily eliminate the later hair-loss method claims. Conversely, expiration or invalidity of the hair-loss patent would not eliminate other patents covering baricitinib.

Is Patent 9,737,469 an Orange Book patent?

The patent is relevant to Orange Book analysis because it covers a method corresponding to an FDA-approved baricitinib use. Orange Book listing depends on FDA submission and listing records, including the patent number and applicable use code.[4]

The relevant regulatory linkage is:

Regulatory item	Status
Drug	Olumiant
Active ingredient	Baricitinib
Applicant	Eli Lilly and Company
FDA application	NDA 207924
U.S. approval	2018 for rheumatoid arthritis
Alopecia areata approval	2022 for adults with severe alopecia areata
Patent relevance	Method-of-use coverage for baricitinib in hair-loss disorders

An Orange Book listing would normally be limited by an FDA use code to the approved indication supported by the patent. The broad patent language covering androgenetic alopecia and other disorders does not mean that every claimed disease is an approved Olumiant indication.

For ANDA litigation, a listed method-of-use patent can generate a Paragraph IV certification if an applicant seeks approval for a product whose proposed labeling includes the protected use. A generic applicant may also use a section viii statement to carve out a patented indication where FDA labeling and regulatory requirements permit the carve-out.[5]

What is the Paragraph IV risk for baricitinib generics?

The principal Paragraph IV risk has two components:

Product and basic-use patents. These may cover baricitinib itself, its preparation, or approved uses such as rheumatoid arthritis.
Hair-loss method patents. Patent 9,737,469 may be relevant where an ANDA applicant seeks approval for alopecia areata or another patented hair-growth indication.

A generic applicant seeking a label that includes severe alopecia areata could face an infringement claim based on the patent’s treatment method. A label that omits alopecia areata may reduce direct regulatory overlap, but commercial conduct, promotional activity, physician instructions, and induced-infringement theories could remain relevant depending on the facts.

The patent does not automatically block generic baricitinib for rheumatoid arthritis if the proposed label excludes the patented hair-loss use. Its commercial blocking power depends heavily on the scope of the generic label and the use code assigned in the Orange Book.

What infringement scenarios create the greatest risk?

Approved severe alopecia areata use

This is the clearest risk scenario. A manufacturer, distributor, or healthcare provider uses or promotes baricitinib for severe alopecia areata during the patent term. Claims 6 and 11 directly target this use.

Alopecia totalis and alopecia universalis

Claims 3 and 9 specifically cover these severe forms. They provide narrower fallback positions if broader alopecia areata claims face validity or construction disputes.

Off-label androgenetic alopecia

Claims 5 and 10 cover human androgenetic alopecia. A company promoting baricitinib for male-pattern or female-pattern hair loss could face a method-of-use challenge even though androgenetic alopecia is not the principal FDA-approved Olumiant indication.

Hair-growth products and compounded preparations

The claims contain no express formulation or route limitation. Oral tablets, compounded products, and potentially topical preparations could fall within the method scope if they contain LY3009104 and are administered for the claimed purpose. The patent does not, however, claim a topical composition as a product.

What formulations are protected by the patent?

Patent 9,737,469 does not appear to claim a formulation as such based on the claims provided. It claims administration of LY3009104.

The absence of formulation limitations has two effects:

A competing baricitinib formulation could still implicate the method claims if used for a covered hair-loss indication.
A different JAK inhibitor or a non-baricitinib formulation would not literally satisfy the active-ingredient limitation.

The patent therefore functions primarily as a use patent. It does not independently establish exclusivity over baricitinib tablets, polymorphs, salts, crystalline forms, excipients, release profiles, or manufacturing methods.

How strong is the patent estate for baricitinib hair-loss treatment?

The patent has strong literal coverage for the exact use of baricitinib in the named hair-loss disorders. Its principal strengths are:

The independent claims identify a specific active ingredient.
The claims cover both treatment and induction of hair growth.
Alopecia areata is expressly recited.
Severe alopecia areata forms have separate dependent claims.
The claims do not require a narrow dose, route, or formulation.
The projected expiration extends into 2034.

Its principal limitations are:

It does not cover other JAK inhibitors.
It does not claim baricitinib as a molecule.
It does not claim a formulation or manufacturing process.
It may face prior-art and obviousness challenges based on earlier JAK inhibitor disclosures and hair-growth research.
Method claims require proof tied to administration and the claimed therapeutic purpose.
The scope of any Orange Book listing may be narrower than the issued claims.

On a commercial basis, the estate is best characterized as a focused, high-value method patent rather than a comprehensive baricitinib exclusivity platform.

Which companies are challenging or competing with baricitinib in alopecia areata?

Baricitinib competes with other oral JAK inhibitors and investigational agents.

Product	Active ingredient	Company	Alopecia areata position
Olumiant	Baricitinib	Eli Lilly	FDA-approved for adults with severe alopecia areata
Litfulo	Ritlecitinib	Pfizer	FDA-approved for severe alopecia areata in eligible patients, including adolescents
Leqselvi	Deuruxolitinib	Sun Pharmaceutical Industries	FDA-approved for severe alopecia areata
CTP-543 programs	Deuruxolitinib predecessor development name	Concert Pharmaceuticals, later Sun	Development program acquired by Sun
Brepocitinib	Brepocitinib	Priovant and collaborators	Investigational or jurisdiction-dependent position

These competitors do not fall within the literal active-ingredient scope of Patent 9,737,469. Their risk is instead determined by their own composition, method-of-use, formulation, and regulatory patents.

Does the patent create biosimilar risk?

No conventional biosimilar pathway applies to baricitinib because baricitinib is a small-molecule drug. A competing manufacturer would generally pursue an ANDA under the Hatch-Waxman framework rather than a biosimilar application under the Public Health Service Act.

The relevant competitive risk is generic entry, not biosimilar substitution. The key issues are Orange Book listings, Paragraph IV certifications, use-code carve-outs, patent litigation, and settlement terms.

What litigation and settlement issues matter?

A complete litigation assessment requires checking the current USPTO maintenance record, FDA Orange Book, and federal court dockets. Patent 9,737,469 should be evaluated across four litigation questions:

Whether it is listed against NDA 207924;
Whether an ANDA applicant has filed a Paragraph IV certification;
Whether Eli Lilly or another patent owner has filed a district-court infringement action;
Whether any settlement permits an agreed generic entry date before November 2034.

The most material settlement term would be the authorized generic or licensed-entry date for an ANDA product with an alopecia areata label. A settlement that permits rheumatoid arthritis-only entry would not necessarily resolve the hair-loss patent risk.

What generic launch scenarios exist?

Scenario 1: Early carved-out launch

A generic launches with rheumatoid arthritis or another nonpatented indication while excluding alopecia areata. This scenario produces partial competition but does not fully erode the patent’s hair-loss position.

Scenario 2: Launch after settlement

The generic enters under a negotiated date before the projected patent expiration, potentially with restrictions on labeling, promotion, or distribution.

Scenario 3: Launch after successful Paragraph IV litigation

The generic enters if the patent is held invalid, unenforceable, not infringed, or otherwise removed as a barrier.

Scenario 4: Full-label entry after patent expiry

A generic launches with alopecia areata labeling after the patent expires, subject to any surviving composition, formulation, or regulatory exclusivity rights.

How does Patent 9,737,469 compare with competing drug patents?

Patent 9,737,469 is narrower in molecule coverage but broader in administration details than many formulation patents.

Attribute	Patent 9,737,469	Typical composition patent	Typical formulation patent
Covers active ingredient	Only as a required treatment agent	Yes	Usually yes, within formulation
Covers therapeutic use	Yes	Sometimes	Sometimes
Covers multiple routes	Potentially, absent claim limitation	No	Usually one dosage form
Covers other JAK inhibitors	No	No	No
Relevance to off-label use	High	Indirect	Variable
Main litigation issue	Infringement and obviousness	Validity and infringement	Claim construction and infringement
Commercial value	Blocks specified baricitinib hair-loss uses	Blocks molecule manufacture and sale	Blocks selected product designs

Key Takeaways

U.S. Patent 9,737,469 is a baricitinib method-of-use patent.
The claims require LY3009104, so they do not cover competing JAK inhibitors.
The core commercial indication is severe alopecia areata, including alopecia totalis and alopecia universalis.
Claims also cover androgenetic alopecia, telogen effluvium, tinea capitis, hypotrichosis, and hereditary hypotrichosis simplex.
The claims do not require a specified dose, route, formulation, or treatment duration.
The projected ordinary expiration date is November 4, 2034.
Generic risk depends on Orange Book listing, use-code scope, Paragraph IV certifications, and any carve-out or settlement.
The patent does not replace composition, formulation, manufacturing, or other baricitinib patents.
Generic entry for non-hair-loss indications may be possible without resolving the full hair-loss method patent.
Baricitinib faces commercial competition from ritlecitinib and deuruxolitinib, but those products are outside the patent’s literal active-ingredient limitation.

FAQs

Is Patent 9,737,469 limited to oral baricitinib tablets?

No. The claims provided do not specify an oral route, tablet, dosage strength, or formulation. The method can potentially cover any administration route that uses LY3009104 for the claimed purpose.

Does the patent cover baricitinib for rheumatoid arthritis?

Not based on the claims provided. The claims are directed to hair-loss disorders and inducing hair growth. They do not claim rheumatoid arthritis treatment.

Can a generic company sell baricitinib for rheumatoid arthritis before 2034?

Potentially, if the generic product avoids applicable composition, formulation, approved-use, and other enforceable patents, and its labeling properly excludes protected hair-loss uses. Patent 9,737,469 alone does not necessarily block a non-hair-loss label.

Does Patent 9,737,469 cover topical ritlecitinib?

No. Ritlecitinib is a different active ingredient from LY3009104. The patent’s JAK-inhibitor language does not override its express limitation to LY3009104.

Is alopecia universalis separately protected?

Yes. Claims 3 and 9 specifically identify alopecia totalis and alopecia universalis as narrower forms of alopecia areata covered by the patent.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,737,469, Methods of treating hair loss using Janus kinase inhibitors.
U.S. Food and Drug Administration. (2022). FDA approves treatment for severe alopecia areata.
United States Code. 35 U.S.C. §§ 154, 156, and 253.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2017). Approved drug products and patent certifications under the Hatch-Waxman Act.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA	⤷ Start Trial
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA	⤷ Start Trial
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-003	May 10, 2022	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	103370076	⤷ Start Trial
China	104334191	⤷ Start Trial
Denmark	2635299	⤷ Start Trial
Denmark	2830662	⤷ Start Trial
European Patent Office	2635299	⤷ Start Trial
European Patent Office	2830662	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,737,469

Which drugs does patent 9,737,469 protect, and when does it expire?

Summary for Patent: 9,737,469